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After returning from Thailand, a 35-year-old man from 
Switzerland was hospitalized with an abscess of the head. 
Material cultured from the abscess and adjacent bone grew 
a gram-negative rod, which was misidentiﬁ  ed by an auto-
mated microbiology system as Burkholderia cepacia. The 
organism was eventually identiﬁ  ed by molecular methods 
as B. pseudomallei.
B
urkholderia pseudomallei, the etiologic agent of me-
lioidosis, can cause pyogenic or granulomatous lesions 
and is endemic to tropic regions, mainly in Southeast Asia 
and northern Australia. This organism is a potential cat-
egory B bioterrorism agent (1). Melioidosis occurs sporadi-
cally in travelers returning from disease-endemic areas, and 
laboratories in regions where this disease is not endemic 
are not familiar with identiﬁ  cation of B. pseudomallei, thus 
potentially leading to misidentiﬁ  cation (2). We report the 
misidentiﬁ  cation of this organism by an automated micro-
biology system.
The Study
On August 20, 2008, a 35-year-old man from Switzer-
land was admitted to the Cantonal Hospital in St. Gallen, 
Switzerland. He had extradural cranial abscess of the right 
parietal area and a defect in adjacent bone. In May and June 
2008, he traveled to Singapore and Malaysia (Kuala Lum-
pur and the Perhentian Islands), then to southwestern (Ko 
Samui, Ko Tau) and northern (Chiang Mai) Thailand where 
he went trekking and river rafting.
The patient did not remember receiving a head injury 
during his trip. Seventeen days after returning to Switzer-
land, he had a swelling in the right parietal area of the head. 
The parietal bulge increased, but puncture by his general 
practitioner showed no aspirate. During the next 7 weeks, 
the bulge became painful and secretion of pus was noted at 
the time of admission.
At admission, his general condition was good and he 
had no signs of systemic inﬂ  ammation. He did not have any 
neurologic deﬁ  cits or other abnormal ﬁ  ndings. Test results 
for complete blood cell count, C-reactive protein and crea-
tinine levels, and liver functions were normal. Computed 
tomography and magnetic resonance imaging of the head 
showed the abscess and a small defect of bone (Figure). 
The abscess and part of the cranial bone were then surgi-
cally removed.
Culture material from the abscess and biopsy speci-
mens of the abscess capsule and the cranial bone grew 
gram-negative, oxidase-positive rods, and smooth creamy 
colonies on sheep blood agar after incubation for 48 hours 
at 35°C. For identiﬁ  cation, a suspension of the isolate was 
prepared and tested in a UNMIC/ID-62 panel of the BD 
Phoenix Automated Microbiology System (Becton Dick-
inson AG, Allschwil, Switzerland) per the manufacturer’s 
instructions. This system identiﬁ  ed the isolate as B. cepacia 
(99% conﬁ  dence). When a species is identiﬁ  ed with >90% 
conﬁ  dence, the Phoenix System gives an identiﬁ  cation re-
sult as a measure of likelihood that the identiﬁ  cation is the 
only correct one.
The patient was discharged from hospital after 5 days 
with a preliminary diagnosis of B. cepacia infection of soft 
tissue (the cranial bone lesion was attributed to trauma). 
He was treated with oral cotrimoxazole (160/800 mg 2× 
a day) for 16 days. The isolate was sensitive to cotrimox-
azole (MIC = 1 mg/L for trimethoprim and 19 mg/L for 
sulfamethoxazole) by the Phoenix System for B. cepacia 
(Becton Dickinson). The isolate was sensitive to imipenem, 
ceftazidime, doxycycline, cotrimoxazole, and tetracycline 
by Etest (AB Biodisk, Solna, Sweden).
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Figure. Computed cranial tomography image of the patient showing 
a swelling at the right parietal area and a small defect of the bone.The diagnosis was regarded as preliminary for the fol-
lowing reasons. First, identiﬁ  cation of B. cepacia by com-
mon automated identiﬁ  cation instruments such as the Phoe-
nix System or VITEK 2 (bioMérieux, Geneva, Switzerland) 
requires conﬁ  rmatory identiﬁ  cation by molecular tests (3). 
Second, an abscess is an uncommon location for B. cepa-
cia (4). Third, the bacterial colonies emitted an unexpected, 
earthy odor. Fourth, the isolate was sensitive to amoxicillin 
(MIC = 8 mg/L) and clavulanate (MIC = 4 mg/L).
To verify identiﬁ  cation of the isolate, a 500-bp frag-
ment of the 16S rRNA gene was ampliﬁ  ed and sequenced 
by using the Fast MicroSeq 500 16S rDNA Bacterial Identi-
ﬁ  cation Kit and a PRISM 310 Genetic Analyzer (both from 
Applied Biosystems, Foster City, CA, USA) according to 
the manufacturer’s instructions. Sequence analysis was 
performed by using MicroSeq ID Microbial Identiﬁ  cation 
Software (Applied Biosystems). The MicroSeq ID 2.0 500-
bp library identiﬁ  ed  B.  pseudomallei (ATCC 23343, gb 
DQ108392.1) with a 446-bp consensus length and 1 mis-
match with B. mallei (NCTC 10247, gb CP000548.1). These 
results suggested that our isolate was B. pseudomallei.
Additional investigations with a ﬂ  agellin C gene–spe-
ciﬁ  c real-time PCR (5) suggested that the isolate was B. 
pseudomallei or B. mallei. Multilocus sequence typing (6) 
showed the allelic proﬁ  le 1/2/3/1/1/2/1, which identiﬁ  ed 
the isolate as B. pseudomallei sequence type 306. This se-
quence type was isolated from serum samples of 2 patients 
in Thailand with invasive melioidosis in 1991 and 2006.
Forty-four days after surgery, new biopsy specimens 
of soft tissue below the parietal scar and a sample of galea 
aponeurotica were cultured for B. pseudomallei after the 
patient received 2 weeks of inadequate therapy with low-
dose cotrimoxazole to determine its drug resistance pattern. 
Cultures yielded only Staphylococcus epidermidis, which 
was regarded as a contaminant. To ensure eradication of 
B. pseudomallei, the patient was treated with imipenem 
(500 mg, 4×/day), cotrimoxazole (400 mg trimethoprim/
day), and leucovorine (15 mg, 3× a week) for 2 weeks and 
later with cotrimoxazole (320 mg trimethoprim/day) and 
leucovorine (15 mg, 3×/week) for 6 months. The patient re-
covered after 6 months; he had a small indentation without 
signs of inﬂ  ammation at the site of the abscess. 
For comparison with the Phoenix System, we retro-
spectively analyzed the isolate by using the API 20NE bio-
chemical test panel V7.0 (bioMérieux). This panel identi-
ﬁ  ed the isolate as B. pseudomallei (proﬁ  le 1156577; 99.9% 
ID, 1.0 T). 
Conclusions
Automated methods for identiﬁ   cation of bacterial 
isolates and testing of antimicrobial drug susceptibility, 
such as the Phoenix System, have become standard in 
most clinical laboratories because they are easy to use and 
turnaround time is rapid. The Phoenix System uses ﬂ  uoro-
genic and chromogenic substrates for its identiﬁ  cation al-
gorithms, a broth-based antimicrobial drug–susceptibility 
testing method, and a data-processing application (Phoe-
nix EpiCenter; Becton Dickinson AG). Unfortunately, B. 
pseudomallei was not in the database of this system, which 
led to misidentiﬁ  cation of our isolate as B. cepacia. Failure 
to correctly identify B. pseudomallei has also been reported 
with another widely used automated system, the Vitek2 
system (7). To identify isolates from patients traveling to 
disease-endemic areas, automated systems should be up-
dated for identiﬁ  cation of B. pseudomallei and other rare 
bacteria that cause severe human infections, are hazardous 
to laboratory personnel, and may be used as bioterrorism 
agents (e.g., Brucella spp. and B. mallei).
Three modes of acquisition (inhalation, ingestion, 
and inoculation) are recognized for B. pseudomallei infec-
tion. Skin and soft tissue infections may occur after minor 
wounds or from hematogenous spread (8). In our patient, 
inoculation of the skin with B. pseudomallei after a minor 
injury in Thailand is probably the mode of infection.
Although laboratory personnel handled cultures of B. 
pseudomallei for identiﬁ  cation and drug resistance testing 
and smelled culture plates without knowing the isolate’s 
identity, none became ill or showed signs of melioidosis. 
According to expert consensus (9), exposure of our labora-
tory personnel was classiﬁ  ed as a low risk. Serum samples 
were stored at –30°C to enable serologic testing for any 
subsequent illness.
Laboratories in regions where B. pseudomallei is not 
endemic should be aware of misdiagnosis of isolates by au-
tomated methods for bacterial identiﬁ  cation and antimicro-
bial drug susceptibility testing. Identiﬁ  cation of Burkhold-
eria spp. by the Phoenix EpiCenter should be conﬁ  rmed by 
molecular methods and by the API 20NE system in sus-
pected cases of B. pseudomallei infection. Because of its 
high rate of accuracy and ease of use, the API 20NE system 
should be used ﬁ  rst for any suspected colony when auto-
mated systems do not contain the adequate proﬁ  le (10).
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etymologia etymologia
Burkholderia
[burk′′hol-dēr′e-ə]
This genus of gram-negative, rod-shaped bacteria comprising animal and plant pathogens was named for 
American plant pathologist Walter H. Burkholder. Dr. Burkholder ﬁ  rst described a particular species of this 
genus, later called Burkholderia cepacia (Latin for “like onion”), after an outbreak of infection in vegetable 
growers in New York State in 1949. Previously known to cause disease in onion bulbs, these organisms are now 
recognized as major bacterial lung pathogens in patients with cystic ﬁ  brosis. B. mallei causes glanders in horses, 
and B. pseudomallei is the etiologic agent of melioidosis in humans and animals. Dr. Burkholder is recognized 
for helping establish the role of bacteria as plant pathogens.
Source:  Dorland’s illustrated medical dictionary, 31st edition. Philadelphia: Saunders; 2007; De Soyza A, Silipo A, Lanzetta R, 
Govan JR, Molinaro A. Chemical and biological features of Burkholderia cepacia complex lipopolysaccarides. Innate Immunity. 
2008;14:127. 